Skip to main content

JDRF has now rebranded to Breakthrough T1D.
Our name has changed, our mission has not.

CGMs available on prescription from August 2022

Anyone with type 1 diabetes can now access real-time continuous glucose monitoring (CGM) through their GP or local hospital. Once prescribed, repeat prescriptions can be collected from local pharmacies.
Breakthrough T1D profile picture
Kate Lawton 2 August 2022

A young woman wearing a continuous glucose monitor

Anyone with type 1 diabetes can now access real-time continuous glucose monitoring (CGM) through their GP or local hospital. Once prescribed, repeat prescriptions can be collected from local pharmacies.

The Dexcom ONE Real Time-Continuous Glucose Monitoring can now be prescribed on the NHS, across all four nations of the UK. This will help put into action the recently updated NICE guidelines in England and Wales on blood glucose monitoring, which say that anyone with type 1 should be offered CGM or flash glucose monitoring as part of standard care.

Patients will be provided with a sensor, transmitter and information on how to use it. The Dexcom ONE has much of the same functions as the G6 device, except for sharing and looping capabilities. Read the differences between the Dexcom devices.

What are CGMs and how can they help people with type 1?

CGMs use a sensor attached to the body which transmits real-time information on glucose levels to a handset or the user’s mobile phone, allowing them to check their glucose levels more often and without the need for painful finger prick tests.

CGMs also alert the user when glucose levels become too low or too high, meaning they are better able to avoid dangerous hypoglycaemia (hypos) or hyperglycaemia (hypers) which can potentially cause long-term complications. They also allow the user to review their glucose trends over time, rather than just giving a snapshot of when the test is taken, as is the case with finger prick tests.

Our work with tech partners

We’ve been working with partners like Dexcom and organisations like NICE and NHS England to help bring about this sort of change for people with type 1.

Our Senior Technology Access Specialist, Lesley Jordan, says: “This is a major breakthrough in the treatment of type 1 diabetes which should allow everyone with type 1 access to this life changing technology. JDRF will work with local decision makers and people with type 1 diabetes to ensure equitable access to glucose monitoring technology as recommended by NICE.”

What do you need to do now?

Whilst this device is now available to be prescribed on the NHS, it may take some time to be rolled out in all areas across the UK. People with type 1 should ask their clinician at their next appointment if it is available in their area, and if not, when it will be.

Read more
A young woman wearing a continuous glucose monitor looks on to a man scanning his sensor.
News
29 October 2024

New report calls for more equal access to type 1 diabetes technology

Our Access for All report, launched today, highlights how far we’ve come with advancements in diabetes technology, but shows that many people still face barriers when trying to access T1D technology.

Read more
A headshot of Professor David Baker in his laboratory.
Research
14 October 2024

Breakthrough T1D-funded researcher wins Nobel Prize

Professor David Baker, a Breakthrough T1D-funded researcher at the University of Washington, has been awarded a Nobel Prize in Chemistry.

Read more
A group of Breakthrough T1D women fundraisers wearing Breakthrough T1D t-shirts and waving flags while smiling.
Breakthrough T1D UK
1 October 2024

JDRF has now become Breakthrough T1D in the UK!

Breakthrough T1D will continue JDRF's journey, accelerating breakthroughs in research, breakthroughs in access to treatments, and bringing the T1D community together to help everyone make their own personal breakthroughs.

Read more
Five people in an office around a table in discussion about work
Research
3 September 2024

Top 10 research priorities for adults living with type 1 diabetes

A new study, which we helped conduct, reveals the most important unanswered questions about type 1 diabetes, based on the priorities of adults in the UK and Ireland.